biostudies-literatureUnknown12Otsyula N<h4>Background</h4>The development of an asexual blood stage vaccine against Plasmodium falciparum malaria based on the major merozoite surface protein-1 (MSP1) antigen is founded on the protective efficacy observed in preclinical studies and induction of invasion and growth inhibitory antibody responses. The 42 kDa C-terminus of MSP1 has been developed as the recombinant protein vaccine antigen, and the 3D7 allotype, formulated with the Adjuvant System AS02A, has been evaluated extensively in human clinical trials. In preclinical rabbit studies, the FVO allele of MSP142 has been shown to have improved immunogenicity over the 3D7 allele, in terms of antibody titres as well as growth inhibitory activity of antibodies against both the heterologous 3D7 and homologous FVO parasites.<h4>MethodsMalaria journal29https://www.ebi.ac.uk/biostudies/studies/S-EPMC3582548biostudies-literatureResults from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.PMC3582548Miller LDiggs CAndagalu BShi MWare LSpring MDAngov EOckenhouse CFOgutu BHeppner DGSoisson LBergmann-Leitner EBallou WROtieno WKoech MDubois MCBennett JRichie NOtieno LKhan FHouse BOtieno GAWaitumbi JPolhemus MGodeaux OCohen JOtsyula NTosh DCummings JfalseResults from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.<h4>Background</h4>The development of an asexual blood stage vaccine against Plasmodium falciparum malaria based on the major merozoite surface protein-1 (MSP1) antigen is founded on the protective efficacy observed in preclinical studies and induction of invasion and growth inhibitory antibody responses. The 42 kDa C-terminus of MSP1 has been developed as the recombinant protein vaccine antigen, and the 3D7 allotype, formulated with the Adjuvant System AS02A, has been evaluated extensively in human clinical trials. In preclinical rabbit studies, the FVO allele of MSP142 has been shown to have improved immunogenicity over the 3D7 allele, in terms of antibody titres as well as growth inhibitory activity of antibodies against both the heterologous 3D7 and homologous FVO parasites.<h4>Methods2013-01-01T00:00:00Z2013 Jan2025-04-22T15:40:52.485Z2019-03-27T01:05:18ZS-EPMC35825482334299610.1186/1475-2875-12-29